# Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

> **NCT03010358** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alexey Danilov, MD** · enrollment: 24 (actual)

## Conditions studied

- Anemia
- B-Cell Prolymphocytic Leukemia
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- Hairy Cell Leukemia
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
- Richter Syndrome

## Interventions

- **DRUG:** Entospletinib
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Obinutuzumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03010358
- **Lead sponsor:** Alexey Danilov, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-04-29
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010358, "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03010358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*